Insight

E. Shyam P. Reddy։ Understanding and Treating HTLV-1

E. Shyam P. Reddy/LinkedIn

Aug 5, 2025, 12:08

E. Shyam P. Reddy։ Understanding and Treating HTLV-1

E. Shyam P. Reddy, Professor and Director of the Cancer Biology Program at Morehouse School of Medicine, shared a post on LinkedIn:

“A research team from Kumamoto University has made a new discovery that reveals how the human T-cell leukemia virus type 1 (HTLV-1) silently persists in the body. Their finding potentially lays the foundation for new therapeutic approaches. Their study, published in Nature Microbiology, identifies a previously unknown genetic “silencer” element that keeps the virus in a dormant, undetectable state.

HTLV-1 is a cancer-causing retrovirus known to lead to adult T-cell leukemia/lymphoma (ATL), an aggressive and often fatal disease. Although most infected individuals remain asymptomatic for life, a fraction eventually develop leukemia or other inflammatory conditions. The virus achieves long-term persistence by entering a “latent” state, during which its genetic material hides inside the host’s genome with minimal activity – evading immune detection.

In this study, the research team, led by Professor Yorifumi Satou from the Joint Research Center for Human Retrovirus, Kumamoto University, identified a specific region within the HTLV-1 genome that functions as a viral silencer. This sequence recruits host transcription factors, particularly the RUNX1 complex, which suppresses the virus’s gene expression. When this silencer region was removed or mutated, the virus became more active, leading to greater immune recognition and clearance in lab models.

Remarkably, when the HTLV-1 silencer was artificially inserted into HIV-1 – the virus that causes AIDS – the HIV virus adopted a more latent-like state, with reduced replication and cell killing. This suggests that the silencer mechanism could potentially be harnessed to design better therapies for HIV as well.

‘This is the first time we’ve uncovered a built-in mechanism that allows a human leukemia virus to regulate its own invisibility. It’s a clever evolutionary tactic, and now that we understand it, we might be able to turn the tables in treatment.’ – said Professor Satou.

The findings offer hope not only for understanding and treating HTLV-1, especially in endemic regions like southwestern Japan, but also for broader retroviral infections.”

Read further.

Title: Intragenic viral silencer element regulates HTLV-1 latency via RUNX complex recruitment

Journal: Nature Microbiology

Authors: Kenji Sugata, Akhinur Rahman, Koki Niimura, Kazuaki Monde, Takaharu Ueno, Samiul Alam Rajib, Mitsuyoshi Takatori, Wajihah Sakhor, Md Belal Hossain, Sharmin Nahar Sithi, M. Ishrat Jahan, Kouki Matsuda, Mitsuharu Ueda, Yoshihisa Yamano, Terumasa Ikeda, Takamasa Ueno, Kiyoto Tsuchiya, Yuetsu Tanaka, Masahito Tokunaga, Kenji Maeda, Atae Utsunomiya, Kazu Okuma, Masahiro Ono, Yorifumi Satou

Read the full article.

E. Shyam P. Reddy

More posts featuring E. Shyam P. Reddy on OncoDaily.

Akhinur Rahman Atae Utsunomiya ATL cancer E. Shyam P. Reddy HIV-1 HTLV-1 Human Retrovirus human T-cell leukemia virus type 1 Kazu Okuma Kazuaki Monde Kenji Maeda Kenji Sugata Kiyoto Tsuchiya Koki Niimura Kouki Matsuda Kumamoto University M. Ishrat Jahan Masahiro Ono Masahito Tokunaga Md Belal Hossain Mitsuharu Ueda Mitsuyoshi Takatori Morehouse School of Medicine Nature Microbiology OncoDaily Oncology Samiul Alam Rajib Sharmin Nahar Sithi Takaharu Ueno Takamasa Ueno Terumasa Ikeda Wajihah Sakhor Yorifumi Satou Yoshihisa Yamano Yuetsu Tanaka

Padraic O’Malley: Meet the Experts of VIRO 2025

Hidden Risks: BRCA Mutations and Breast Implants - CancerWorld

FDA Breakthrough Therapy Designation for Iza-bren: Advancing Treatment for EGFR-Mutant NSCLC

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Author?

LOCKTAC Molecular Glues Are Changing the Rules of Drug Discovery - Amgen